Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 25Unknown 5Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 6Sarcoma 5Thoracic 2Plasma cell 2Lymphoid 2Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 62Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Sunitinib × Thoracic × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03463460 2026-03-23

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡